The central focus of the Cytogenetics Shared Resource (CYT) is to provide high quality cytogenetic and molecular cytogenetic analysis of human and animal model research samples in a timely, cost-effective manner for members of the Mayo Clinic Cancer Center (MCCC) and other investigators within the Mayo research community. External requests are accommodated with discretion. The highly specialized cytogenetic and molecular cytogenetic services and equipment utilized to provide such services to MCCC users would be impractical to institute into multiple individual laboratories. These services are ideally provided in a central location and in a Shared Resource environment, which eliminates the need to duplicate expensive equipment and technologist training and analysis time. Services within the CYT include: Cell Culture, Routine Chromosome Analysis, DNA and RNA fluorescence in situ Hybridization (FISH), and Custom DNA Probe Production as well as RNA FISH Probe Production and a Tyramide Signal Amplification (TSA) protocol. Together, with the investigator, the CYT assists in determining how these techniques can be utilized to meet the evolving needs of their research studies. In addition to the test menu described above, the CYT staff also provides specialized training to investigators for FISH set-up, and microscope use in an effort to minimize investigator cost and economize technologist time. The staff that makes up the CYT have over 75 years of combined cytogenetic and molecular cytogenetic expertise. The capability provided by the CYT is not present in any other Shared Resource facility or research laboratory at Mayo Clinic. The 6 highly qualified and experienced staff members (3.6 FTE) provide expert consultation in experimental design, troubleshooting, modification of experiments, and interpretation of results. The staff also serves to help facilitate the translation of molecular cytogenetic discoveries into clinically available diagnostic assays. In the past grant cycle (2013- 2017), the CYT had a total of 208 users, representing 10 of the 10 MCCC Programs active at the time. Among our 208 users, 84 (40.4%) are MCCC members. Of these 84 investigators, 57 (68%) have active peer- reviewed funding. During these past 5 years, the CYT supported the production of 36 peer-reviewed publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113591
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications